$8.36 Billion is the total value of Carlyle Group Inc.'s 8 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATC | Atotech Ltd | $3,373,116,000 | -14.0% | 153,672,703 | 0.0% | 40.35% | -1.0% | |
| ZI | Sell | ZoomInfo Technologies Inc | $2,523,742,000 | -11.2% | 42,245,437 | -4.6% | 30.19% | +2.2% |
| OCDX | Ortho Clinical Diagnostics H | $2,203,858,000 | -12.8% | 118,106,000 | 0.0% | 26.36% | +0.4% | |
| ONEM | 1Life Healthcare Inc | $150,829,000 | -36.9% | 13,612,681 | 0.0% | 1.80% | -27.4% | |
| VTRU | Vitru Ltd | $98,694,000 | +12.1% | 6,246,471 | 0.0% | 1.18% | +29.0% | |
| SMHI | Seacor Marine Hldgs Inc | $9,264,000 | +137.4% | 1,147,989 | 0.0% | 0.11% | +170.7% | |
| SPNT | SiriusPoint Ltd | $968,000 | -8.0% | 129,408 | 0.0% | 0.01% | +9.1% | |
| ONE | Exit | Onesmart Intl Ed Group Ltdsponsored ads | $0 | – | -7,860,000 | -100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Wesco Aircraft Hldgs Inc | 28 | Q4 2019 | 16.8% |
| Seacor Marine Hldgs Inc | 22 | Q3 2023 | 1.1% |
| Enviva Partners LP | 21 | Q2 2020 | 31.5% |
| Enduro Rty Tr | 21 | Q1 2018 | 2.8% |
| USA Compression Partners LP | 20 | Q2 2018 | 28.5% |
| Pattern Energy Group Inc | 20 | Q3 2018 | 16.2% |
| Concord Med Svcs Hldgs Ltd | 19 | Q3 2017 | 1.1% |
| Superior Energy Svcs Inc | 19 | Q3 2017 | 0.7% |
| Cobalt Intl Energy Inc | 17 | Q1 2017 | 11.0% |
| Sequential Brnds Group Inc N | 17 | Q1 2020 | 1.7% |
View Carlyle Group Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Complete Solaria, Inc. | September 22, 2023 | 2,745,879 | 5.7% |
| Carlyle Credit Income Fund | September 14, 2023 | 4,785,628 | 41.0% |
| eFFECTOR Therapeutics, Inc. | August 18, 2023 | 4,829,891 | 7.8% |
| Vera Therapeutics, Inc. | August 02, 2023 | 1,872,764 | 4.2% |
| Reneo Pharmaceuticals, Inc. | May 09, 2023 | 2,730,457 | 8.2% |
| EXICURE, INC. | April 13, 2023 | 287,137 | 3.4% |
| SPRUCE BIOSCIENCES, INC. | February 23, 2023 | 3,734,518 | 9.2% |
| Vaxcyte, Inc. | February 10, 2023 | 2,070,724 | 2.6% |
| NuCana plc | August 11, 2022 | 3,353,134 | 6.4% |
| QuidelOrtho Corp | June 06, 2022 | 12,460,183 | 18.6% |
View Carlyle Group Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| ARS | 2024-04-18 |
| DEF 14A | 2024-04-18 |
| DEFA14A | 2024-04-18 |
| 8-K | 2024-04-03 |
| PRE 14A | 2024-04-03 |
| 4 | 2024-04-02 |
| SC 13G | 2024-03-29 |
| 8-K | 2024-03-27 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Carlyle Group Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.